Q4 2024 Medicure Inc Earnings Call Transcript
Key Points
- Medicure Inc (MCUJF) reported a slight increase in net revenue for 2024, reaching $21.9 million compared to $21.7 million in 2023.
- ZYPITAMAG sales through traditional insurance channels increased to $3 million from $2.4 million, attributed to greater utilization through insurance formularies.
- Marley drug's net revenue grew by 12.5% from $9.6 million in 2023 to $10.8 million in 2024, driven by an increase in ZYPITAMAG and generic medication sales.
- The company remains debt-free with cash reserves increasing to $7.2 million from $6.4 million at the end of 2023.
- Medicure Inc (MCUJF) acquired Gateway Medical Pharmacy and signed an agreement to acquire West Olympia Pharmacy, expanding its retail pharmacy segment and creating synergies with Marley Drugs.
- Medicure Inc (MCUJF) recorded a net loss of approximately $1 million for 2024, up from a net loss of $922,000 in the previous year.
- AGGRASTAT revenue decreased from $9.7 million in 2023 to $8.1 million in 2024 due to pricing pressures from increased competition.
- Adjusted EBITDA for 2024 was negative $437,000, a significant decline from $1.9 million in 2023.
- General and administrative expenses increased to $4.8 million from $4.1 million, primarily due to higher professional and legal fees.
- Research and development expenses rose to $3.1 million from $2.4 million, driven by ongoing development projects, including MC1.
Welcome to Medicare's earnings conference call for the quarter and year end of December 31, 2024. My name is Holly, and I will be your operator for today's call. At this time, all participants are in listen-only mode. Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events, and expectations which are made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20 F.
Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded, and today's date is April 29, 2025. I would now like to turn the conference call over to Doctor Albert Friesen, Chief Executive Officer of Medicare Inc. Please go ahead, Doctor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
